The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere
The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere
复制标题
DOI：
10.1016/s0090-3019(99)00103-2
复制
发表时间：
1999-10-01
影响因子：
--
通讯作者：
Berger, MS
中科院分区：
文献类型：
--
作者：
Keles, GE;Anderson, B;Berger, MS
背景我们回顾分析了92例接受大脑半球多形性胶质母细胞瘤手术的患者(107例)术前和术后的肿瘤体积，以确定影响肿瘤进展时间(TTP)和总存活率的因素。方法肿瘤体积的量化是基于先前描述的方法，该方法包括在计算机断层扫描或磁共振成像上对增强的肿瘤进行计算机图像分析。结果在所分析的变量中，术前卡氏评分、化疗、切除率、残留量对手术总有效率有显著影响(P<；0.001，0.001)。影响生存的因素有年龄(P<；0.05)、术前KPS(P=0.05)、术后KPS(P<；0.005)、VRD(P<；0.0005)和VRD(P<；0.0001)。肿瘤切除程度和肿瘤残留量是影响大脑半球多形性胶质母细胞瘤患者中位肿瘤进展时间和中位生存期的重要因素。(C)1999年，爱思唯尔科学公司。
BACKGROUNDWe retrospectively analyzed preoperative and postoperative radiographic tumor volumes in 92 patients who underwent hemispheric glioblastoma multiforme operations (107) to determine the factors that affect time to tumor progression (TTP) and overall survival.METHODSQuantification of tumor Volumes was based on a previously described method involving computerized image analysis of contrast enhancing tumor on computerized tomography or magnetic resonance imaging scans. RESULTS Among the variables analyzed, preoperative Karnofsky Performance Status (KPS) (p < 0.05), chemotherapy (p < 0.05), percent of resection (POR) (p < 0.001), and volume of residual disease (VRD) (p < 0.001) had a significant effect on TTP. Factors that affected survival were age (p < 0.05), preoperative KPS (p = 0.05), postoperative KPS (P < 0.005), FOR (p < 0.0005), and VRD (p < 0.0001). Greater resections did not compromise the quality of life, and patients without any residual disease had a better postoperative KPS than those patients who received less than total resections.CONCLUSIONSThe extent of tumor removal and the amount of residual tumor volume, documented on postoperative imaging studies, are highly significant factors affecting the median time to tumor progression and median survival for patients with glioblastoma multiforme of the cerebral hemisphere. (C) 1999 by Elsevier Science Inc.